NCT07638956Not yet recruiting
ICG in Colon Cancer
A Prospective Study of Indocyanine Green (ICG) Fluorescence-Guided Lymphatic Mapping During Laparoscopic Colon Cancer Resection
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the role of indocyanine green (ICG) injection in fluorescence-guided lymphatic mapping during laparoscopic colon cancer resection. This is a single-center prospective single-arm pilot clinical study that will include at least 25 patients with resectable colon cancer. All enrolled patients will undergo intraoperative subserosal ICG-guided lymphatic mapping before dissection, and intravenous ICG perfusion assessment before anastomosis. The primary goal is to determine the proportion of analyzable pN+ patients in whom all metastatic lymph nodes identified on final histopathology are located within the ICG-mapped lymphatic basin.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 5 Jun 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Tanta University
- Diseases
- Colorectal cancer
- NCT number
- NCT07638956
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 1 Jun 2026 to the primary completion date, 1 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known allergy or contraindication to ICG (including prior anaphylaxis to ICG; severe hypersensitivity history per anesthesia assessment).
- Planned palliative resection only.
Other illness
- Emergency surgery (obstruction/perforation with sepsis) requiring urgent operation.
Lab values
- Severe hepatic failure (because ICG clearance is hepatobiliary) or other contraindication determined by anesthesia team.
Other
- Pregnancy or breastfeeding.
- ASA physical status IV or patients otherwise deemed unfit for elective curative colectomy.
Who the study is looking for
- Age \>= 18 years.
- \- Histologically confirmed colon adenocarcinoma.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.